Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative MedicineCell Therapy

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753383

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1753383

Bioproduction

PUBLISHED:
PAGES: 380 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Bioproduction Market to Reach US$61.6 Billion by 2030

The global market for Bioproduction estimated at US$28.1 Billion in the year 2024, is expected to reach US$61.6 Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Biologics & Biosimilars, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$32.6 Billion by the end of the analysis period. Growth in the Vaccines segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.7 Billion While China is Forecast to Grow at 19.0% CAGR

The Bioproduction market in the U.S. is estimated at US$7.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.4 Billion by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 12.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Global Bioproduction Market - Key Trends & Drivers Summarized

Why Is Bioproduction Gaining Strategic Importance in the Future of Industrial and Therapeutic Manufacturing?

Bioproduction is rapidly emerging as a critical enabler of modern industrial and biopharmaceutical manufacturing, offering a biologically-driven alternative to traditional synthetic production methods. It refers to the use of living organisms-such as bacteria, yeast, algae, or mammalian cells-to produce a wide range of products, including therapeutic proteins, enzymes, biofuels, vaccines, monoclonal antibodies, and specialty chemicals. As the global demand for biologics, sustainable materials, and eco-friendly manufacturing practices rises, bioproduction is positioned as a highly scalable and sustainable solution that aligns with the needs of the 21st-century economy. In the pharmaceutical sector, bioproduction is indispensable for developing complex biologics that cannot be synthesized chemically, such as insulin, erythropoietin, and various cell and gene therapies. Outside pharma, bioproduction plays a key role in producing biodegradable plastics, plant-based meat alternatives, and bio-based ingredients in the cosmetics, food, and agriculture industries. Its ability to produce high-purity, high-potency substances using renewable feedstocks makes it an attractive alternative to petroleum-based manufacturing. Moreover, bioproduction supports circular economy models, reduces waste, and lowers greenhouse gas emissions, making it a priority in global decarbonization strategies. With its convergence of biology, engineering, and data science, bioproduction is no longer just a research niche-it’s an industrial revolution in motion, shaping how we create, consume, and conserve resources across industries.

How Are Emerging Technologies and Tools Advancing the Scope and Efficiency of Bioproduction?

Technological innovation is driving the next wave of efficiency, scalability, and customization in bioproduction systems. Key breakthroughs in synthetic biology and metabolic engineering are allowing scientists to program microorganisms with precision, optimizing biosynthetic pathways to maximize yield and minimize by-product formation. CRISPR-Cas and other genome-editing tools are enabling highly targeted genetic modifications, accelerating strain development and enhancing product consistency. Continuous bioprocessing and modular bioproduction platforms are replacing traditional batch processes, offering reduced downtime, higher throughput, and better scalability. Advanced bioreactor designs-including single-use systems, perfusion reactors, and microfluidic platforms-are improving flexibility and enabling real-time adjustments during production. Meanwhile, AI and machine learning algorithms are being employed to predict cell behavior, optimize fermentation parameters, and detect anomalies across upstream and downstream operations. Integration with IoT devices and process analytical technology (PAT) is further enhancing monitoring capabilities, allowing real-time data acquisition and dynamic process control. Furthermore, advancements in downstream processing-such as high-resolution chromatography, membrane filtration, and precipitation technologies-are improving product recovery and purity, especially in high-value therapeutic applications. Cell-free bioproduction systems are also gaining attention for their ability to bypass the limitations of living systems, enabling faster prototyping and on-demand synthesis. As digitalization, automation, and biological sciences continue to converge, the bioproduction industry is evolving into a smart, adaptive, and data-driven ecosystem capable of meeting diverse product demands while ensuring regulatory compliance and process robustness.

Which Industries and Geographies Are Driving the Expansion of the Global Bioproduction Ecosystem?

Bioproduction is experiencing accelerated adoption across a broad spectrum of industries and regions, each leveraging biological manufacturing to achieve strategic, regulatory, or sustainability goals. The pharmaceutical and biotechnology sectors remain the largest consumers of bioproduction systems, especially for the production of monoclonal antibodies, recombinant proteins, vaccines, and cell-based therapies. The food and beverage industry is increasingly adopting bioproduction techniques to create alternative proteins, fermented functional ingredients, and bioactive compounds used in supplements and nutraceuticals. In the energy sector, companies are using engineered microbes to convert biomass into renewable fuels like ethanol, biodiesel, and hydrogen. The cosmetics and personal care sectors are also embracing bioproduction to develop eco-friendly fragrances, colorants, and emulsifiers. Regionally, North America leads the market, driven by robust R&D infrastructure, a high concentration of biotech firms, and favorable regulatory frameworks that support innovation. Europe follows closely, with countries like Germany, Switzerland, and the Netherlands focusing on bioeconomy strategies, sustainable chemistry, and green manufacturing. Asia-Pacific is the fastest-growing region, with rapid industrialization, growing investment in life sciences, and supportive government initiatives in countries such as China, India, Japan, and South Korea. Latin America and Africa, while still emerging, are beginning to tap into bioproduction potential by leveraging local biodiversity and agricultural waste streams. In all these regions, public-private partnerships, international research collaborations, and rising consumer demand for sustainable products are fueling the bioproduction market. Whether in therapeutic, industrial, or environmental applications, bioproduction is becoming a global movement that cuts across traditional industry lines and national boundaries.

What Is Fueling the Growth in the Global Bioproduction Market?

The growth in the global bioproduction market is driven by a dynamic combination of scientific innovation, commercial demand, regulatory momentum, and global sustainability goals. One of the most significant growth drivers is the escalating demand for biologics and advanced therapies, particularly in the treatment of chronic, genetic, and rare diseases. These therapies often require highly specialized production systems that only bioproduction platforms can offer. Simultaneously, consumer preferences are shifting toward sustainable, ethically produced, and bio-based products in sectors ranging from personal care to agriculture-prompting companies to invest in bioproduction technologies that align with ESG criteria. Governments and regulatory agencies are also playing a pivotal role by supporting bioproduction through funding, tax incentives, and streamlined approval processes for bio-based innovations. As countries pursue climate action targets and circular economy models, bioproduction stands out for its ability to reduce reliance on petrochemicals, minimize waste, and produce energy and materials in a more environmentally friendly way. Additionally, the scalability and flexibility of modern bioproduction systems make them suitable for both large-scale industrial applications and localized, on-demand production-providing resilience and adaptability in volatile supply chain environments. The growth of CDMOs and biofoundries is further accelerating market development by offering outsourced, cost-effective access to high-end bioproduction capabilities. Together, these factors are not only fueling rapid expansion but are also setting the stage for bioproduction to become a foundational technology in a bio-based global economy-reshaping the future of how goods and medicines are produced, consumed, and sustained.

SCOPE OF STUDY:

The report analyzes the Bioproduction market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Biologics & Biosimilars, Vaccines, Cell & Gene Therapies, Nucleic Acid Therapeutics); Application (Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application, Cardiovascular Diseases Application); End-Use (BioPharmaceuticals Companies End-Use, Contract Manufacturing Organizations End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • BioVectra
  • Boehringer Ingelheim BioXcellence
  • Catalent, Inc.
  • Charles River Laboratories
  • Cytiva
  • Emergent BioSolutions
  • FUJIFILM Diosynth Biotechnologies
  • Genscript Biotech
  • KBI Biopharma
  • Lonza Group
  • MilliporeSigma (Merck KGaA)
  • Novartis
  • Pfizer CentreOne
  • Resilience (National Resilience, Inc.)
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Sartorius AG
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36388

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Bioproduction - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Explosive Growth in Biologics and Cell-Based Therapies Throws the Spotlight on Scalable Bioproduction Platforms
    • Personalized Medicine and Rare Disease Treatments Spur Demand for Flexible, Small-Batch Bioproduction Capabilities
    • Here's How Continuous Bioprocessing Is Transforming the Efficiency and Economics of Bioproduction
    • Advancements in Single-Use Systems Drive Cost-Effective and Contamination-Free Production Environments
    • Rise of Contract Development and Manufacturing Organizations Strengthens the Business Case for Outsourced Bioproduction
    • Surging Vaccine and mRNA Therapeutics Pipelines Expand the Addressable Market for Modular Bioproduction Facilities
    • Digitalization and Process Automation Fuel the Emergence of Smart Bioproduction Systems with Real-Time Monitoring
    • Here's the Story: How Cell and Gene Therapy Are Reshaping Facility Design and Custom Bioproduction Workflows
    • Increased Regulatory Focus on Quality by Design Principles Accelerates Adoption of PAT and Data-Driven Bioprocessing
    • Synthetic Biology and Genome Editing Tools Enable High-Yield Production of Novel Bioproducts and Platforms
    • Environmental Sustainability and Energy Efficiency Goals Drive Innovation in Green Bioproduction Methods
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bioproduction Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bioproduction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics & Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics & Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Biologics & Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cell & Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cell & Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cell & Gene Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Nucleic Acid Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Nucleic Acid Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for BioPharmaceuticals Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for BioPharmaceuticals Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for BioPharmaceuticals Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Contract Manufacturing Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Contract Manufacturing Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Contract Manufacturing Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Rheumatoid Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hematological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hematological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hematological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • CHINA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Bioproduction by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Bioproduction by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • INDIA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Bioproduction by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Bioproduction by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!